131 related articles for article (PubMed ID: 3912618)
1. Chemotherapy with cyclophosphamide, adriamycin, and 5-fluorouracil compared to chemotherapy plus hormonal therapy with tamoxifen in the treatment of advanced breast cancer: an interim analysis.
Perry MC; Kardinal CG; Weinberg V; Ginsberg SJ; Hughes A; Wood W
J Steroid Biochem; 1985 Dec; 23(6B):1135-40. PubMed ID: 3912618
[TBL] [Abstract][Full Text] [Related]
2. Chemoendocrine therapy vs chemotherapy alone for advanced breast cancer in postmenopausal women: preliminary report of a randomized study.
Kardinal CG; Perry MC; Weinberg V; Wood W; Ginsberg S; Raju RN
Breast Cancer Res Treat; 1983; 3(4):365-71. PubMed ID: 6365209
[TBL] [Abstract][Full Text] [Related]
3. Chemohormonal therapy in advanced carcinoma of the breast: Cancer and Leukemia Group B protocol 8081.
Perry MC; Kardinal CG; Korzun AH; Ginsberg SJ; Raich PC; Holland JF; Ellison RR; Kopel S; Schilling A; Aisner J
J Clin Oncol; 1987 Oct; 5(10):1534-45. PubMed ID: 3655856
[TBL] [Abstract][Full Text] [Related]
4. A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer.
Bennett JM; Byrne P; Desai A; White C; DeConti R; Vogel C; Krementz E; Muggia F; Doroshow J; Plotkin D
Invest New Drugs; 1985; 3(2):179-85. PubMed ID: 3894279
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Albain KS; Barlow WE; Shak S; Hortobagyi GN; Livingston RB; Yeh IT; Ravdin P; Bugarini R; Baehner FL; Davidson NE; Sledge GW; Winer EP; Hudis C; Ingle JN; Perez EA; Pritchard KI; Shepherd L; Gralow JR; Yoshizawa C; Allred DC; Osborne CK; Hayes DF;
Lancet Oncol; 2010 Jan; 11(1):55-65. PubMed ID: 20005174
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant systemic therapy for women with node-positive breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.
CMAJ; 1998 Feb; 158 Suppl 3():S52-64. PubMed ID: 9484279
[TBL] [Abstract][Full Text] [Related]
7. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma.
Bennett JM; Muss HB; Doroshow JH; Wolff S; Krementz ET; Cartwright K; Dukart G; Reisman A; Schoch I
J Clin Oncol; 1988 Oct; 6(10):1611-20. PubMed ID: 3049953
[TBL] [Abstract][Full Text] [Related]
8. Increasing the response rate to cytotoxic chemotherapy by endocrine means.
Lippman ME; Cassidy J; Wesley M; Young RC
J Steroid Biochem; 1985 Dec; 23(6B):1173-80. PubMed ID: 3005774
[TBL] [Abstract][Full Text] [Related]
9. Responses to chemotherapy or chemohormonal therapy in advanced breast cancer patients treated previously with adjuvant chemotherapy. A subset analysis of CALGB Study 8081.
Kardinal CG; Perry MC; Korzun AH; Rice MA; Ginsberg S; Wood WC
Cancer; 1988 Feb; 61(3):415-9. PubMed ID: 3338011
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group.
Boccardo F; Rubagotti A; Bruzzi P; Cappellini M; Isola G; Nenci I; Piffanelli A; Scanni A; Sismondi P; Santi L
J Clin Oncol; 1990 Aug; 8(8):1310-20. PubMed ID: 2199618
[TBL] [Abstract][Full Text] [Related]
11. Treatment of metastatic breast cancer in estrogen receptor positive patients. A randomized trial comparing tamoxifen alone versus tamoxifen plus CMF.
Bezwoda WR; Derman D; De Moor NG; Lange M; Levin J
Cancer; 1982 Dec; 50(12):2747-50. PubMed ID: 6754067
[TBL] [Abstract][Full Text] [Related]
12. Treatment of metastatic breast cancer in premenopausal women using CAF with or without oophorectomy: an Eastern Cooperative Oncology Group Study.
Falkson G; Gelman RS; Tormey DC; Falkson CI; Wolter JM; Cummings FJ
J Clin Oncol; 1987 Jun; 5(6):881-9. PubMed ID: 3585444
[TBL] [Abstract][Full Text] [Related]
13. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy with or without tamoxifen in postmenopausal patients with late breast cancer. A randomized study.
Boccardo F; Rubagotti A; Rosso R; Santi L
J Steroid Biochem; 1985 Dec; 23(6B):1123-7. PubMed ID: 3912616
[TBL] [Abstract][Full Text] [Related]
15. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).
Davidson NE; O'Neill AM; Vukov AM; Osborne CK; Martino S; White DR; Abeloff MD
J Clin Oncol; 2005 Sep; 23(25):5973-82. PubMed ID: 16087950
[TBL] [Abstract][Full Text] [Related]
16. [Management of advanced breast cancer in post-menopausal women. A comparative trial of hormonal therapy, chemotherapy, and a combination of both].
Clavel B; Cappelaere JP; Guerin J; Klein T; Pommatau E; Berlie J
Sem Hop; 1982 Sep; 58(34):1919-23. PubMed ID: 6293073
[TBL] [Abstract][Full Text] [Related]
17. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer.
Berry DA; Muss HB; Thor AD; Dressler L; Liu ET; Broadwater G; Budman DR; Henderson IC; Barcos M; Hayes D; Norton L
J Clin Oncol; 2000 Oct; 18(20):3471-9. PubMed ID: 11032587
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer--a randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative Group. Danish Breast Cancer Cooperative Group (DBCG).
Andersson M; Madsen EL; Overgaard M; Rose C; Dombernowsky P; Mouridsen HT
Eur J Cancer; 1999 Jan; 35(1):39-46. PubMed ID: 10211086
[TBL] [Abstract][Full Text] [Related]
19. Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study.
Sledge GW; Hu P; Falkson G; Tormey D; Abeloff M
J Clin Oncol; 2000 Jan; 18(2):262-6. PubMed ID: 10637238
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group) trial.
Boccardo F; Rubagotti A; Amoroso D; Sismondi P; Genta F; Nenci I; Piffanelli A; Farris A; Castagnetta L; Traina A
Eur J Cancer; 1992; 28(2-3):673-80. PubMed ID: 1591091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
